B1MG

Personalised medicine brings significant socio-economic benefits, including faster, more accurate diagnostics, the development of pharmacogenomics and the advancement of preventative medicine, resulting in better health and quality of life for patients as well as more efficient national health systems. The EU-funded B1MG project will provide the support and coordination structure for the European 1+ Million Genomes initiative based on the commitment of 20 EU states and Norway to work ‘towards access to at least 1 million sequenced genomes in the EU by 2022’. These countries will engage a range of stakeholders to support the creation of a pan-European genome-based health data infrastructure, encompassing data quality and exchange standards, access protocols and legal guidance.